Ally Bridge Group
No summary available yet.
Ally Bridge is essentially a cross-border specialist that made their name in the biotech boom, with some impressive exits like their early Moderna stake. They're genuinely well-connected in both US and Chinese markets, which is valuable if you need Asia-Pacific partnerships or expansion. However, they're pretty narrow in focus - if you're not in healthcare or don't have a clear Asia angle, you're probably not their cup of tea. They tend to be hands-on with portfolio companies, which some founders love and others find intrusive. The China connection is both their superpower and potential liability depending on current geopolitical winds.
- —Best for: Healthcare/biotech companies needing Asia-Pacific market access
- —Watch out for: Heavy operational involvement and narrow sector focus
- —Known for: Strong cross-border networks and biotech expertise
Ally Bridge Group focuses on cross-border investments between Asia and the West, particularly in healthcare, technology, and financial services. They leverage their network across China, Hong Kong, and the US to help companies expand globally.
Series A to growth stage investments in healthcare (biotech, medtech), fintech, and enterprise software, with a strong emphasis on companies that can benefit from Asia-Pacific market access or partnerships
Former Goldman Sachs managing director with extensive Asia-Pacific experience. Known for his deep healthcare expertise and cross-border deal execution. Founders describe him as highly connected but demanding on execution.
Former McKinsey partner with healthcare and biotech focus. She leads many of their life sciences investments and is known for her operational expertise. Portfolio companies value her strategic guidance.
Have a specific question about Ally Bridge Group?
Ask Bernie →